Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Dearnaley

Showing results (31-40 of 85) with videos related to

Pageof 9
Sort By:
European Urology|December 3, 2014
A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancerRamachandran Venkitaraman, David Lorente, Vedang Murthy, et al.
Ebiomedicine|January 28, 2023
Multi-candidate immunohistochemical markers to assess radiation response and prognosis in prostate cancer: results from the CHHiP trial of radiotherapy fractionationAnna Wilkins, Barry Gusterson, Holly Tovey, et al.
The British Journal of Radiology|April 2, 2019
Realizing the potential of magnetic resonance image guided radiotherapy in gynaecological and rectal cancerIngrid M White, Erica Scurr, Andreas Wetscherek, et al.
BJU International|November 8, 2008
Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling timeMichael K Ng, Nicholas Van As, Karen Thomas, et al.
Clinical and Translational Radiation Oncology|June 22, 2018
Methodology for tissue sample collection within a translational sub-study of the CHHiP trial (CRUK/06/016), a large randomised phase III trial in localised prostate cancerAnna Wilkins, Christine Stuttle, Shama Hassan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2015
Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADTLaurence Klotz, Chris O'Callaghan, Keyue Ding, et al.
BJU International|July 18, 2023
International Society of Urological Pathology (ISUP) Gleason Grade Groups stratify outcomes in the CHHiP Phase 3 prostate radiotherapy trialDavid Dearnaley, Clare L Griffin, Pedro Silva, et al.
European Urology|January 14, 2014
Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agentsCarmel J Pezaro, Aurelius G Omlin, Amelia Altavilla, et al.
International Journal of Radiation Oncology, Biology, Physics|January 23, 2010
Expression of Bcl-2, p53, and MDM2 in localized prostate cancer with respect to the outcome of radical radiotherapy dose escalationRoy Vergis, Catherine M Corbishley, Karen Thomas, et al.
Physics in Medicine and Biology|March 15, 2017
Iterative framework for the joint segmentation and CT synthesis of MR images: application to MRI-only radiotherapy treatment planningNinon Burgos, Filipa Guerreiro, Jamie McClelland, et al.
Pageof 9

Showing results (31-40 of 85) with videos related to

Sort By:
Pageof 9
European Urology|December 3, 2014
A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancerRamachandran Venkitaraman, David Lorente, Vedang Murthy, et al.
Ebiomedicine|January 28, 2023
Multi-candidate immunohistochemical markers to assess radiation response and prognosis in prostate cancer: results from the CHHiP trial of radiotherapy fractionationAnna Wilkins, Barry Gusterson, Holly Tovey, et al.
The British Journal of Radiology|April 2, 2019
Realizing the potential of magnetic resonance image guided radiotherapy in gynaecological and rectal cancerIngrid M White, Erica Scurr, Andreas Wetscherek, et al.
BJU International|November 8, 2008
Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling timeMichael K Ng, Nicholas Van As, Karen Thomas, et al.
Clinical and Translational Radiation Oncology|June 22, 2018
Methodology for tissue sample collection within a translational sub-study of the CHHiP trial (CRUK/06/016), a large randomised phase III trial in localised prostate cancerAnna Wilkins, Christine Stuttle, Shama Hassan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2015
Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADTLaurence Klotz, Chris O'Callaghan, Keyue Ding, et al.
BJU International|July 18, 2023
International Society of Urological Pathology (ISUP) Gleason Grade Groups stratify outcomes in the CHHiP Phase 3 prostate radiotherapy trialDavid Dearnaley, Clare L Griffin, Pedro Silva, et al.
European Urology|January 14, 2014
Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agentsCarmel J Pezaro, Aurelius G Omlin, Amelia Altavilla, et al.
International Journal of Radiation Oncology, Biology, Physics|January 23, 2010
Expression of Bcl-2, p53, and MDM2 in localized prostate cancer with respect to the outcome of radical radiotherapy dose escalationRoy Vergis, Catherine M Corbishley, Karen Thomas, et al.
Physics in Medicine and Biology|March 15, 2017
Iterative framework for the joint segmentation and CT synthesis of MR images: application to MRI-only radiotherapy treatment planningNinon Burgos, Filipa Guerreiro, Jamie McClelland, et al.
Pageof 9